Goldman Sachs Group Inc. Has $193,000 Position in Lyell Immunopharma, Inc. $LYEL

Goldman Sachs Group Inc. lowered its holdings in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 42.8% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 358,592 shares of the company’s stock after selling 268,729 shares during the quarter. Goldman Sachs Group Inc. owned about 2.42% of Lyell Immunopharma worth $193,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Lyell Immunopharma by 13.4% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company’s stock worth $197,000 after purchasing an additional 36,555 shares in the last quarter. Almitas Capital LLC boosted its stake in Lyell Immunopharma by 136.3% in the first quarter. Almitas Capital LLC now owns 2,482,606 shares of the company’s stock worth $1,336,000 after purchasing an additional 1,432,086 shares in the last quarter. Nuveen LLC acquired a new position in Lyell Immunopharma in the first quarter worth $345,000. Acadian Asset Management LLC boosted its stake in Lyell Immunopharma by 204.2% in the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company’s stock worth $354,000 after purchasing an additional 443,614 shares in the last quarter. Finally, AQR Capital Management LLC boosted its stake in Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after purchasing an additional 154,327 shares in the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Stock Up 0.9%

Shares of LYEL opened at $12.83 on Monday. Lyell Immunopharma, Inc. has a 12-month low of $7.65 and a 12-month high of $32.00. The firm has a market capitalization of $246.46 million, a PE ratio of -0.53 and a beta of -0.19. The stock’s fifty day simple moving average is $11.74 and its 200-day simple moving average is $10.25.

Lyell Immunopharma (NASDAQ:LYEL) last released its earnings results on Tuesday, August 12th. The company reported ($2.89) earnings per share for the quarter, beating the consensus estimate of ($3.80) by $0.91. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%.The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.00 million. Analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on LYEL shares. HC Wainwright reaffirmed a “neutral” rating and set a $10.00 price target on shares of Lyell Immunopharma in a research note on Tuesday, June 24th. Wall Street Zen raised Lyell Immunopharma from a “sell” rating to a “hold” rating in a research note on Monday, September 1st. One research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Reduce” and an average target price of $15.00.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.